Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults비활성화된 전체 바이러스 면역증강제 COVID-19 백신 VLA2001의 안전성 및 면역원성: 건강한 성인을 대상으로 한 무작위, 용량 증량, 이중 맹검 1/2상 임상 시험Clinical Trial Published on 2022-09-012022-09-12 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adjuvanted vaccine binding clinical development clinical trial conducted convalescent sera coronavirus COVID-19 COVID-19 vaccine CpG CpG 1018 dose Dose escalation dose-escalation double-blind evaluate expressing Frequency geometric mean titre GMT groups headache healthy High dose high-dose group highest dose IFN-γ IgG immunogenicity inactivated Inactivated vaccine injection Local medium N protein neutralizing antibody Open-label optimal dose outcome participant Phase 3 primary immunogenicity priming Randomized randomized trial RBD-binding IgG RBD-binding IgG antibody reactive recruited Registered reported S protein S protein binding IgG antibody Safety SARS-CoV-2 SARS-CoV-2 neutralizing antibody second vaccination severity significantly significantly higher statistically systemic reaction T-cell tested titre Tolerability vaccination Vaccine VLA2001 was selected Whole-virus vaccine. [DOI] 10.1016/j.jinf.2022.06.009 PMC 바로가기 [Article Type] Clinical Trial
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial건강한 성인을 대상으로 한 단일 용량 V590(rVSV-SARS-CoV-2 Vaccine)의 근육 내 안전성 및 면역원성: 1상 무작위 배정, 이중 맹검, 위약 대조, 용량 범위 시험 결과Clinical Trial Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] Administered administration Adults adverse event adverse events AEs anti-SARS-CoV-2 Antibody responses comparable COVID-19 COVID-19 vaccine Day dose double-blind Endpoint fatigue global pandemic headache healthy highest dose immunogenicity Inc. Injection-site pain intramuscular lower dose neutralisation neutralising antibody response Older overcome Part participant pfu Phase 1 phase 1 study Placebo placebo-controlled plaque plaque-forming unit plaque-forming units primary endpoints PRNT50 randomised receive reduction Registration reported Result Safety SARS-CoV-2 SARS-CoV-2 nucleocapsid seronegative seronegative participant seronegative participants seropositive serum Sharp spike-specific antibody response stomatitis subsidiary Trial USA V590 Vaccine vesicular stomatitis vesicular stomatitis virus vesicular stomatitis virus (VSV) virus VSV [DOI] 10.1016/j.ebiom.2022.104138 PMC 바로가기 [Article Type] Clinical Trial
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™SARS-COV-2 항바이러스 치료제 Paxlovid™의 적시 개발을 지원하는 Nirmatrelvir의 포괄적인 비임상 안전성 평가Article Published on 2022-08-012022-09-11 Journal: International journal of toxicology [Category] 치료제, [키워드] 3CL administration Antiviral Arrhythmias assessment blood pressure cardiovascular caused clinical development Clinical pathology coagulation time Comprehensive conducted COVID-19 COVID-19 patient COVID-19 patients death decrease decreases development dose Drug safety Effect Efficacy Endpoint enhancer enzyme functional heart rate high risk highest dose Hospitalization Increases increases in induce Infection locomotor male MPro nervous system Nirmatrelvir not affect pathology Paxlovid pharmacokinetic Potential produced profile protease RATs Replication respiratory rate Ritonavir Safety safety pharmacology SARS-CoV-2 SARS-CoV-2 virus Support Supporting target tested the SARS-CoV-2 virus toxicities Toxicity toxicology transaminase transaminases Treatment treatment of COVID-19 were assessed [DOI] 10.1177/10915818221095489 PMC 바로가기 [Article Type] Article
Determinants of access to the SARS-CoV-2 vaccine: a preliminary approachResearch Published on 2021-08-142022-10-29 Journal: International journal for equity in health [Category] COVID-19, MERS, [키워드] affected affecting applied approach China collected confirmatory factor analysis coronavirus disease correlation country COVID COVID-19 COVID-19 tests COVID-19 vaccine criteria deaths determinant distribution eight elapsed extreme first dose GDP greater highest dose India less median age Pearson question receiving Result Russia SARS-CoV-2 vaccination SEM supplementary material Support t-test the disease the SARS-CoV-2 The United States the vaccine United Kingdom vaccination Vaccine Vaccine distribution vaccine dose vaccine doses Vaccines variable variables [DOI] 10.1186/s12939-021-01520-4 PMC 바로가기 [Article Type] Research
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)Research article Published on 2021-08-132022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] Antigen can be used Cell clinical Clinical research clinical status clinical trial conducted convalescent COVID-19 COVID-19 patient development Donor dose dose-escalation European evaluate Evidence feasibility feasible finding foundation funding highest dose HLA Hospitalization Immunotherapy infused intermediate dose leukocyte lowest lymphocyte lymphopenia memory memory T cell memory T cells Mortality network parameter participant patients phase Pneumonia provide reduce Regional reported Safe SARS-CoV-2 score Serious Adverse Event severity of symptoms Spanish subject supported Symptom T cell T-lymphocyte therapy Treatment [DOI] 10.1016/j.eclinm.2021.101086 [Article Type] Research article
Liver fat storage is controlled by HNF4α through induction of lipophagy and is reversed by a potent HNF4α agonistArticle Published on 2021-06-112022-10-04 Journal: Cell Death & Disease [Category] 신약개발, [키워드] Administered agonist benfluorex cells clearance Control CYP26A1 downstream downstream genes drug expression fat highest dose increased expression Lipid signalling liver mice NAFLD nontoxic occurred pathway reduction reversed secretion SPNS2 steatosis Target validation therapeutic [DOI] 10.1038/s41419-021-03862-x PMC 바로가기 [Article Type] Article
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model햄스터 모델에서 SARS-CoV-2에 대한 Favipiravir 항바이러스 효능Article Published on 2021-03-192022-09-10 Journal: Nature Communications [Category] SARS, 변종, 신약개발, 유전자 메커니즘, 치료제, [키워드] analyses animals anti-SARS-CoV-2 antiviral activity Antiviral effect antiviral efficacy antiviral molecule antiviral molecules clinical trial clinical trials comparable decrease determine dosage dose Drug development Effect Efficacy evaluated Evidence Experimental models of disease Favipiravir fitness Genetic genomes High dose highest dose human clinical trials humans in viral incorporation Infection infectious titer infectious titers initiated lack lung Lungs mechanism of action Mutation pharmacokinetic plasma drug reduction Repurposed drug Repurposed drugs required RNA viruses SARS-CoV-2 tested the disease Therapeutics Tolerance Toxicity Treatment variety Viral viral genome viral genomes viral infectivity [DOI] 10.1038/s41467-021-21992-w PMC 바로가기 [Article Type] Article
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2Antiviral Agents Published on 2021-03-012022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19, [키워드] activity acute respiratory syndrome Administered administration adverse event agent Antiviral AUC C max clinically Concentration coronavirus COVID-19 declined decrease dose Dose escalation double-blind EIDD-1931 EIDD-2801 Electrocardiography evaluated exceeded expected first in human geometric healthy volunteers highest dose Human incidence influenza viruses Laboratory median time MERS-CoV Middle East Mild molnupiravir multiple dose multiple doses no decrease novel oral pandemic pharmacokinetics Phase 1 Placebo placebo-controlled study plasma plasma concentration Randomized Rash reached Registered reported respiratory syndrome coronavirus Ribonucleoside analog ribonucleoside analogue RNA viruses Safety SARS-CoV SARS-CoV-2 Serious Adverse Events single dose subject tested Tolerability vital signs [DOI] 10.1128/AAC.02428-20 PMC 바로가기 [Article Type] Antiviral Agents
Extreme Exposure to Filtered Far‐UVC: A Case Study †Special Issue Research Article Published on 2021-02-032022-10-28 Journal: Photochemistry and Photobiology [Category] COVID-19, MERS, SARS, [키워드] appear change contribute Critical dose Efficacy and safety Evidence exposure to extreme faster filtered highest dose inactivation Inc. information Japan Laboratory limit occurred promote promoted Radiation Research resolved SARS‐CoV‐2 skin Tokyo Type ultraviolet viruses wavelength while [DOI] 10.1111/php.13385 PMC 바로가기 [Article Type] Special Issue Research Article
Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In VitroResearch Article Published on 2020-12-112022-10-29 Journal: mBio [Category] COVID-19, SARS, [키워드] ACE2 ACE2 receptor Angiotensin-converting enzyme 2 (ACE2) antiviral activity binding Cell cell line cells Complete controls Coronavirus disease 2019 (COVID-19) CPE CPEs Critical Cytopathic effect cytotoxicity disrupt evaluated expected highest dose host cell Human human Angiotensin-converting enzyme human lung Human plasma hydrocarbon stapling infecting Infection inhibitory concentration linear MOST overexpressing peptide peptides Prevent prevented proteolytic receptor SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly stability stapled peptides tested therapy treat Vaccine Vero E6 cell virus [DOI] 10.1128/mBio.02451-20 PMC 바로가기 [Article Type] Research Article